DERM vs UNH

Journey Medical (DERM) maintains its high-risk, high-reward profile, primarily driven by the upcoming PDUFA decision for DFD-29 in Q3 2026. The Q1 2026 earnings report showed positive signs with a revenue beat ($15.96M vs. $15.47M consensus), 21% YoY growth, narrowing losses (EPS $(0.08)$ vs $(0.18)$ YoY), and positive Adjusted EBITDA of $0.62M. Cash and equivalents also increased to $27.22M, prov...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...